Effect of sodium glucose cotransporter 2 inhibitors on atrial tachy‐arrhythmia burden in patients with cardiac implantable electronic devices

• DOI: 10.1111/jce.15996
• Publication Date: 2023-07-15T16:43:52Z
• Authors: Arwa Younis; Tania Arous; Robert Klempfner; Adnan Kharsa; Scott McNitt; Susan Schleede; Bronislava Polonski; Zeinab Abdallah; Ruppinder Buttar; Christopher Bodurian; Chadi Tabaja; Hagai D. Yavin; Farooq Shamroz; Oussama M. Wazni; Steven D. Wittlin; Mehmet Aktas; Ilan Goldenberg
• Keywords: Clinical endpoint

Abstract Introduction Use of sodium glucose cotransporter 2 inhibitors (SGLT2i) was associated with a reduction in atrial fibrillation hospitalizations. Therefore, we aim to evaluate the effects SGLT2i on tachy‐arrhythmias (ATA) patients cardiac implantable electronic devices (CIEDs). Methods All 13 888 consecutive implanted CIED two tertiary medical centers were enrolled. Treatment assessed as time dependent variable. The primary endpoint total number ATA. Secondary endpoints included ventricular (VTA), ATA and VTA, death. events independently adjudicated blinded treatment. Multivariable propensity score modeling performed. Results During follow‐up 24 442 patient years there 62 725 10 324 VTA events. ( N = 696) significant 22% risk (hazard ratio [HR] 0.78 [95% confidence interval {CI} 0.70–0.87]; p < .001); ATA/VTA (HR CI 0.71–0.85]; 35% all‐cause mortality 0.65 0.45–0.92]; .015), but not significantly 0.92 0.80–1.06]; .26). lower burden heart failure (HF) among diabetes (HF: HR 0.68, 95% 0.58–0.80, .001 vs. Diabetes: 0.95, 0.86–1.05, .29; for interaction between indication burden). Conclusion Our real world findings suggest that HF patients, those had pronounced when compared SGLT2i.